Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that Canada's Drug Agency (CDA) has ...

Shares of Merck & Co. Inc. MRK inched 0.44% higher to $101.17 Thursday, on what proved to be an all-around mixed trading ...

Are you a print subscriber? Activate your account. By Garett Sloane - 37 min 55 sec ago By Ewan Larkin - 1 hour 7 min ago By E.J. Schultz - 1 hour 7 min ago By Tim Nudd - 1 hour 7 min ago By Brian ...

Green’s sister, Ragine Williams, 30, does DEI reporting, recruiting, and outreach for the technology firm SEI. She agreed that coming together with other women was inspiring, even if some may have ...

Guggenheim lowered the firm’s price target on Merck (MRK) to $130 from $137 and keeps a Buy rating on the shares. While noting shares are down about 2.6% since the company reported Q3 earnings last ...

Deutsche Bank lowered the firm’s price target on Merck (MRK) to $140 from $145 and keeps a Buy rating on the shares following the Q3 ...

Shares of Merck & Co. Inc. MRK slipped 0.48% to $103.73 Tuesday, on what proved to be an all-around mixed trading session for ...

This year, pharmaceutical giant Merck (NYSE: MRK) is it: The drugmaker's shares are down by 2% in 2024 while the broader S&P 500 is up by 21%. Even when we zoom out, Merck hasn't performed ...

Oct 23 (Reuters) - Merck (MRK.N), opens new tab has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the privately held biotech firm ...

(Reuters) - Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the privately held biotech firm said on Wednesday. As part of ...